601 Versus Ranibizumab in Patients With Pathological Myopic Choroidal Neovascularization (pmCNV)
Status:
Recruiting
Trial end date:
2023-07-31
Target enrollment:
Participant gender:
Summary
To evaluate the safety and efficacy of intravitreal recombinant humanized anti-VEGF
monoclonal antibody in patients with visual impairment due to pmCNV